Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP657 | DOI: 10.1530/endoabs.49.EP657

ECE2017 Eposter Presentations: Diabetes, Obesity and Metabolism Obesity (81 abstracts)

Association between cardiometabolic risk indicators and FGF 19 in healthy Saudi individuals of different BMI grades

Ghada Ajabnoor 1, , Yomna Hajjar 2, , Suhad Bahijri 1, & Anwar Borai 2,


1Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 2Saudi Diabetes Study Research Group, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 3Postgraduate Student, Department of Clinical Biochemistry, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; 4King Abdullah International Medical Research Center (KAIMRC), College of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah, Saudi Arabia.


Background: Fibroblast growth factor 19 (FGF19) is an enterokine derived from the ileum, and synthesized in response to release of bile acids following food ingestion. It was proposed to be an important regulator of the postprandial adaptive metabolic response. by stimulating glycogen and protein synthesis in the liver, and down regulating glucose production after a meal. There is limited research investigating the association between FG-19 and metabolic dysregulation in overweight and obese Saudi subjects.

Aim: To study association of circulating FGF 19 in healthy individuals of different BMI grades, with some cardiometabolic risk indicators.

Subjects and methods: Healthy adults aged 19–36 years were recruited. Height, and weight were measured to calculate body mass index (BMI). Sixty males and 60 females were included in the study, divided equally between BMI categories (underweight, normal, overweight and obese). Waist, hip, and neck circumference (WC, HC, NC) were measured. Glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C), insulin, FGF19 and highly sensitive CRP (hs-CRP) were estimated in fasting serum samples, and low-density lipoprotein cholesterol (LDL-C), Atherogenic index of plasma (AIP), and homeostatic model assessment-insulin resistance (HOMA-IR) were calculated.

Results: No significant correlation (P=0.457), or difference in means of FGF19 was noted between different BMI categories (P=0.905). A negative significant correlation was found between FGF19 and WC, NC, and LDL-C: HDL-C ratio (r=−0.203, P=0.027, r=−0.297, P=0.002, r=−0.187, P=0.041 respectively).

Conclusions: Serum FGF19 levels do not appear to be related to general obesity expressed as BMI. However, it was found to be associated negatively with indicators of abdominal, and upper torso obesity, reported to be associated with increased cardiometabolic risk, indicating the relationship of FGF19 with this risk. The strong correlation between FGF19 and serum LDL-C:HDL-C;a well established indicator of cardiometabolic risk; validate the link further.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.